Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Regeneron Pharmaceuticals Inc (REGN), Apple Inc. (AAPL), Best Buy Co., Inc. (BBY): 3 Monday Morning Upgrades I’m Buying Now

Page 1 of 2

There were countless market-moving upgrades on Monday morning — but here are three in particular that I believe are most attractive and that I personally am buying.

A Bullish Day for Biotech

The entire biotech space is moving higher in response to the bid for Onyx Pharmaceuticals, especially those with Orphan blockbusters. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is one of those stocks, but also got an upgrade to produce an extra boost.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

Piper upgraded the stock from “Neutral” to “Overweight” with a $274 price target. Shared traded higher, erasing some of the 20% loss that it has posted over the last six weeks. If Piper’s target is correct, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) would trade with a market cap near $27 billion (currently $22.75 billion) and would trade at 10.8 times next year’s sales and 45 times next year’s earnings.

While these metrics may appear expensive, keep in mind that it has an approved drug, EYLEA, with peak sales potential of $4 billion; they also have two other approved drugs and a pipeline with 12 products, including the Phase 3 cholesterol drug Alirocuma. This one product is estimated to have peak sales potential of $3.5 billion in the U.S. alone. Therefore, when you consider its pipeline, current product offerings, and its potential, you can see that the upside is quite high for this company.

“Sentiment is bad. Make that horrible”

The above quote was issued by Raymond James with its upgrade of Apple Inc. (NASDAQ:AAPL) to “Strong Buy” from “Buy.” Raymond James believes that the integration of its ecosystem into cars, TVs, and appliances could present a new high-growth market for the company.

Aside from the reasons noted, Apple Inc. (NASDAQ:AAPL) is cheap. It is still producing growth and is trading at just seven times next year’s earnings (minus cash) and at 2.2 times sales. In a previous article, I showed how Apple Inc. (NASDAQ:AAPL) is actually worth $700 but is going through a transition where it shifts from growth to maintenance.

In the past, this has always worked well for other companies such as Netflix, Inc. (NASDAQ:NFLX) or Green Mountain Coffee Roasters Inc. (NASDAQ:GMCR), but does seem to produce short-term weakness. Thus, I agree with Raymond James that shifting sentiment and new product offerings will drive the stock higher.

Another Retail Turnaround

Credit Suisse initiated coverage on Best Buy Co., Inc. (NYSE:BBY) with a bullish $40 price target and an “Outperform” rating. Credit Suisse believes that new leadership was a good idea for the retailer and likes what it sees from the company in its turnaround process.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!